To determine the need and appropriate timing of catheter removal in patients with candidemia, the records for 404 patients with cancer and central venous catheters (CVCs) who developed candidemia during the period of 1993-1998 were retrospectively reviewed. Of the total 404 cases of candidemia, 241 (60%) were due to a primary source, 111 (27%) were catheter related, and 52 (13%) were secondary cases of candidemia caused by a source other than the catheter. Multivariate analysis showed that catheter removal р72 h after onset improved response to antifungal therapy exclusively in patients with catheter-related candidemia ( ). P p .04 Clinical characteristics that suggested a noncatheter source for the candidemia were disseminated infection ( ), previous chemotherapy ( ), previous corticosteroid therapy ( ), and poor response to P ! .01 P ! .01 P p .02 antifungal therapy ( ). CVC removal р72 h after onset should be considered in patients with suspected P ! .03 catheter-related candidemia who have no evidence of dissemination, recent corticosteroid therapy, or chemotherapy.
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Central venous catheters (CVCs) have become essential and widely used devices in the modern care of hospitalized patients. Several studies have identified the CVC as a risk factor for the development of candidemia [1] [2] [3] [4] [5] [6] . Previous use of a CVC was found to be an independent risk factor for nosocomial candidemia in multivariate regression analysis of a matched case-control study [1] . In another study, by multiple logistic regression analysis, it was also shown that prolonged (190-day) CVC placement is the best predictor of candidemia in children with HIV infection [2] .
Should the CVC be removed in a patient with candidemia? Several studies investigated the impact of CVC removal on outcome (death or persistence and recurrence of the candidemia) [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . However, none of these studies determined the appropriate time for CVC removal or the subpopulation of patients (patients with CVC-related candidemia, compared with those with candidemia originating from a noncatheter source) that would best benefit from such intervention. In this study, we reviewed 404 episodes of candidemia that occurred in patients with cancer who have indwelling CVCs and determined by univariate and multivariate analyses the impact of CVC removal at various time points on the outcome of the bloodstream infection.
PATIENTS, MATERIALS, AND METHODS

Study population.
All patients with candidemia diagnosed antemortem at the University of Texas M.D. Anderson Cancer Center (Houston) during the period of 1 January 1993 through January 1998 were identified by blood cultures positive for Candida species through the records of the Department of Microbiology. The hospital course of the patients was retrospectively reviewed to determine the following demographic characteristics: age, sex, the underlying disease (including its stage and therapy), and the presence of a CVC.
Potential risk factors before the onset of the fungal bloodstream infection were examined, including antibiotic therapy within 30 days before infection, parenteral hyperalimentation, immunosuppressive therapy (antineoplastic agents and corticosteroids) within 30 days before infection, admission to intensive care unit, duration of hospitalization, and antifungal prophylaxis. Factors that could affect the outcome of the infection were also determined, such as the degree and duration of neutropenia, as well as the presence of dissemination at the onset of candidemia. The type, dose, and duration of antifungal therapy were also identified. A subgroup of the patients included in this current study was included in previously published studies [21] [22] [23] . However, the impact of catheter removal on outcome was not determined in the previously published studies.
CVC characteristics.
Only patients with an indwelling CVC placed for у24 h before the onset of candidemia were included in this evaluation. Excluded were patients with multiple CVCs that, although inserted before the first blood culture positive for Candida species, were removed at different times. The site of the CVC and the number and dates of exchange of the CVC before its removal were also determined. In addition, the type, site, and duration of placement of other catheters were also identified. The outcome of the candidemia in terms of response to antifungal therapy was determined in relation to the timing of the CVC removal from the first positive blood culture result at 24-h time intervals, with a special focus on the following time intervals: (1) early removal within 72 h (3 days), (2) delayed removal within 120 h (5 days), and (3) no removal of the catheter, with the CVC was retained for 17 days after the first positive blood culture result. CVC removal was distinguished from CVC exchange over a guidewire by the fact that the CVC removed was not replaced by a new catheter at the same vascular site.
Microbiologic methods. According to our hospital policy, the intravascular segment (catheter tip) from all CVCs of patients with candidemia was cultured by means of the semiquantitative roll plate method described by Maki et al. [24] . All organisms identified from either the blood or catheter cultures were speciated according to standard microbiologic methods. Blood cultures were performed by the lysis-centrifugation method (isolator system; Wampole Laboratories), which quantify the number of colonies (colony-forming units [cfu]) per milliliter of blood.
Definitions. Candidemia was defined as the isolation of Candida species from у1 blood culture specimen associated with clinical manifestations of bloodstream infections, such as fever, chills, or hypotension [3] . Candidemia cases were classified as primary cases, secondary non-catheter-related cases, and catheter-related cases. Primary candidemia was referred to as a bloodstream infection caused by Candida species without a defined organ or catheter source. Therefore, the term "primary" was used to refer to candidemia of unknown origin in this population of patients with cancer in which the candidemia could originate from the gastrointestinal tract, the catheter, or several other sources. Secondary candidemia was defined, in accordance with Pittet and Wenzel [25] , as a bloodstream infection caused by Candida species with a documented concurrent infection or colonization caused by the same Candida species at a body site other than the catheter.
The definitions of catheter-related candidemia were based on the US Centers for Disease Control and Prevention guidelines, Infectious Diseases Society of America guidelines, and other reports [26] [27] [28] . Definite catheter-related candidemia was defined as a primary candidemia with either the catheter tip being colonized with the same Candida species isolated from the bloodstream or the quantitative blood culture sample obtained through the CVC showing a у5-fold greater colony count than the concurrent peripheral venous quantitative blood culture. Significant colonization of the catheter was defined as the isolation of 115 cfu of any Candida species by use of the roll-plate semiquantitative culture method [24] . Dissemination was defined as the hematogenous spread of the Candida infection to noncontiguous sites that occurs after the onset of the candidemia [13] .
Response was defined as the resolution of all clinical manifestations (such as fever or chills) of the candidemia with sterilization of the bloodstream. Failure to respond was defined as persistence of the clinical signs and symptoms of the fungal infection, persistence of blood cultures positive for Candida species, development of a Candida infection at a new body site, or some combination of these outcomes.
Data analysis. Frequencies and descriptions of the demographic and clinical characteristics of the patient population and subgroups of CVC-related and secondary candidemia were generated. Univariate and multivariate analyses were performed to determine the effect of catheter removal on outcome of candidemia and to identify the predictors of catheter-related infection. Univariate analyses were performed by the x 2 test or Fisher's exact test for the categorical variables, as appropriate. Continuous data were analyzed by use of the Wilcoxon signed rank test for nonnormally distributed data. Univariate predictors that were significant at the level were examined in P р .1 a multivariate logistic regression model for significance by the Wald test with backward elimination. All tests were conducted as 2-tailed tests.
was considered significant. SPSS for P ! .05 Windows, version 11.0 (SPSS), was used for all analyses.
RESULTS
Characteristics of patients.
There were 475 patients who had a CVC for у24 h before the onset of the candidemia episodes. Of those, 71 patients with multiple CVC and different CVC (37) 60 (25) C. parapsilosis 74 (18) 26 (23) 1 (2) 47 (20) C. glabrata 71 (18) 11 (10) 16 (31) 44 (18) C. krusei 53 (13) 5 (5) 1 (2) 47 (20) C. tropicalis 45 (11) 11 (10) 10 ( On the basis of these findings, we reclassified patients with primary candidemia into 2 groups. Patients with primary candidemia and any of 3 nonoutcome clinical characteristics (no evidence of dissemination of the fungemia and no recent corticosteroid or chemotherapy 1 month before the onset of the candidemia) were considered to possibly have non-catheterrelated primary candidemia (210 cases), whereas those without these 3 clinical characteristics were considered to possibly have catheter-related primary infection (31 cases).
CVC removal and response. Analysis of all 404 candidemia episodes in patients with a CVC generally showed that the earlier the CVC is removed, the better the response is to antifungal therapy (figure 1). More than one-half (223 [55%] of 404) of the CVCs were removed у72 h after onset of candidemia. CVC removal within 48 and 72 h from the first positive blood culture result had a significant impact on response for all cases of candidemia ( , figure 1A ). CVC removal P p .04 within 120 h from the first positive blood culture showed a trend in favor of the CVC removal ( ; figure 1B ). Analy-P p .06 sis of 2 subsets of patients (one consisting of patients with definite CVC-related candidemia and the other consisting of those with secondary non-catheter-related candidemia) showed differing results (figure 1). Early CVC removal within 24, 48, and 72 h after the first positive blood culture result had a significantly favorable impact on response of catheter-related candidemia to antifungal therapy ( ; figure 1A) . CVC P ! .05 removal within 120 h had a significantly favorable impact on the response of CVC-related candidemia, but to a lesser extent than did removal within 72 h ( ; figure 1B) . Catheter P p .05 removal (whether early or delayed) had no impact on the response of secondary non-catheter-related candidemia to antifungal therapy ( ; figure 1) . P у .7 Most (210 [87%] of 241) of the cases of primary candidemia (241 cases) were possibly non-catheter related and were associated with either disseminated candidiasis or having received corticosteroids or chemotherapy within 1 month before the onset of the candidemia. CVC removal at 72 h after the first positive blood culture result had no effect on the response in this subset of patients with possible non-catheter-related primary candidemia (184 cases). These patients lived у72 h after the onset of candidemia (56% vs. 53%;
). The number P p .78 of patients with possibly catheter-related primary candidemia was small (31 patients); however, CVC removal at 72 h was associated with high (90%) response to antifungal therapy, compared with 75% if the catheter was retained. This difference (90% vs. 75%) was not significant because of the small number of cases and, thus, a very limited power of 3%. Catheter removal within 7 days after the first positive blood culture result had no impact on response for all cases of candidemia as well as the subset groups of catheter-related primary and secondary candidemias ( figure 1) .
The impact of CVC removal on the response of candidemia was studied in a multivariate logistic regression analysis model that included all univariate predictors of response to antifungal therapy that tended to be significant at . Early removal P р .01 of the catheter within 72 h after the onset of candidemia had a significant impact on response to antifungal therapy for patients with catheter-related candidemia (table 3), whereas removal at 120 h had no significant impact, as determined by multivariate analysis. Multivariate analysis revealed that cath- eter removal at various points had no impact on the outcome of candidemia for all patients or those with primary or secondary non-catheter-related candidemia.
Predictors of response and outcome. The type of antifungal therapy (fluconazole vs. amphotericin B and its lipid formulations) had no significant impact on outcome, as determined by multiple logistic regression analysis. However, as shown in table 3, multiple logistic regression analysis revealed that corticosteroid use within 30 days before the onset of candidemia and neutropenia at onset of the candidemia were predictors of poor response in all cases of candidemia and also in the subset of patients with catheter-related candidemia. CVC retention for 172 h after the onset of candidemia was a predictor of poor outcome in catheter-related candidemia cases, but not for all cases or those with secondary non-catheterrelated source. Underlying hematologic malignancy and admission to the intensive care unit were predictors of poor response for all patients with candidemia and those with secondary non-catheter-related candidemia, but not for those patients with catheter-related candidemia. Fungemia caused by non-parapsilosis species of Candida was a predictor of poor response for all cases of candidemia, but this was not significantly associated with poor response for those patients with catheter-related or secondary infections.
As shown in table 4, on its own, response to antifungal therapy was an index marker of outcome in terms of morbidity (duration of hospitalization and candidemia) and mortality (death associated with candidemia).
DISCUSSION
Data from this study show that catheter removal within 72 h of the first positive blood culture is necessary for patients with catheter-related candidemia, but is not necessary for those with a non-catheter-related source of the candidemia. In addition, in a patient with cancer who has an indwelling CVC and candidemia, the catheter should be suspected as the source of the fungemia if the patient has not received any chemotherapy or corticosteroids within 30 days before the bloodstream infection and if there is no evidence of secondary foci or dissemination of the candidiasis at the onset of the candidemia.
Catheter-related candidemia may be associated with serious complications such as septic thrombosis, endocarditis, and meningitis [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . In a multivariate analysis of nosocomial bloodstream infections, Candida species were the only organisms independently predictive of an unfavorable outcome [32] . Therefore, the data derived from this current study suggesting an improved outcome with early removal of the CVC is of special importance, given the relatively high morbidity and mortality associated with catheter-related bloodstream infections caused by Candida species.
The impact of CVC removal on the outcome of candidemia has been evaluated in several studies [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . These studies consisted of 6 prospective studies [7] [8] [9] [10] [11] [12] and 8 retrospective studies [13] [14] [15] [16] [17] [18] [19] [20] . In most of these studies, catheter removal improved outcome by decreasing mortality or decreasing the duration of fungemia and recurrence of infection [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . However, in none of these studies was there a clear distinction in terms of the impact of CVC removal on those patients with catheter-related candidemia versus those with a noncatheter or indeterminate source for the fungemia. Most of the prospective studies cited above included large numbers of patients (range, 145-427 patients) [7] [8] [9] [10] . In a multicenter prospective observational study including 427 consecutive patients with candidemia, Nguyen et al. [7] showed that vascular catheter retention proved to be a significant independent risk factor for the persistence of candidemia after 72 h of antifungal therapy ( ) and was associated with P ! .05 higher mortality ( ). Nucci et al. [8] analyzed the pos-P ! .001 sible risk factor for death among 145 patients with nosocomial candidemia. Catheter retention was found to be the only variable associated with increased risk of death in multivariate analysis (OR, 4.22; 95% CI, 2-11.6). In a similar multivariate analysis of a prospective study involving nosocomial candidemia by Hung et al. [9] , CVC retention was one of the prognostic factors that adversely influenced outcome. A more recent prospective observational study involving 104 neonates with candidemia and CVCs showed that early CVC removal (within 72 h after onset) was associated with shorter duration of candidemia, and failure to remove the CVC was associated with increased mortality [12] .
Similarly, most retrospective studies that analyzed the impact of CVC removal on the outcome of candidemia favored catheter removal [13] [14] [15] [16] [17] [18] [19] [20] . Five of these retrospective studies involved only univariate analysis and small numbers of assessable patients [15] [16] [17] [18] [19] . The largest 3 retrospective studies included multivariate analyses [13, 14, 20] . Anaissie et al. [13] reviewed findings for 416 patients with cancer who had a CVC when they developed candidemia at our institution. CVC retention was associated with poor outcome, death, or persistent infection, compared with the outcomes for patients who underwent guidewire exchange or removal of the catheter ( ). Luz-P p .002 zati et al. [14] showed, through multivariate analysis of a retrospective study involving 189 adult patients with nosocomial candidemia, that CVC removal was independently associated with a decrease in mortality. In contrast to all the studies cited above, Goodrich et al. [20] showed that CVC removal had the opposite expected effect on the duration of candidemia in a study involving 102 bone marrow transplant recipients, whereby CVC removal was associated with more prolonged duration of candidemia ( ) than was catheter retention. P p .001 On the basis of the data from these studies, recent guidelines for the treatment of candidiasis written by experts in the field recommend that initial nonmedical management of candidemia should include removal of all existing central venous catheters [33] . However, recent reviews on candidemia [34, 35] debated this conclusion, stating, "the automatic removal of all vascular catheters to treat all cases of candidemia should be reevaluated" [35] . Unlike previous studies, this current study assesses the impact of catheter removal on outcome at various points in time and in different subpopulations of patients. Strict defi- nitions of catheter-related candidemia were based on recent guidelines [27] and on the use of quantitative blood and catheter culture results. In addition, this study included a large number of candidemia cases analyzed by multivariate analysis, including a relatively large number of documented catheterrelated candidemia episodes, whereby all catheters removed were cultured by semiquantitative technique. In a multivariate logistic regression analysis that included other variables that may influence outcome, our study showed that early catheter removal is beneficial in patients with CVCrelated candidemia. However, catheter removal might not be beneficial in patients with a definite noncatheter source or with a possible gastrointestinal source, such as patients who have received previous chemotherapy р1 month before the onset of the candidemia. Therefore, on the basis of the analysis of the data pertaining to this study, it is prudent to base the decision of early removal on positive clinical diagnostic predictors suggestive of a CVC-related source for the candidemia. On the basis of our data, these predictors include: (1) no previous chemotherapy р1 month before the onset of the can-didemia (anticancer chemotherapy is not only a risk factor for neutropenia but also for gastrointestinal toxicity that would enhance the risk of candidemia from the gut rather than the catheter [36, 37] ), (2) no previous corticosteroid therapy (in multivariate analysis, the use of corticosteroids was recently identified as a significant risk factor associated with breakthrough candidemia in 2 retrospective clinical studies [38, 39] ), and (3) no evidence of dissemination of the candidemia or other apparent secondary source for the candidemia.
Most (87%) of the 241 patients with cancer who had primary candidemia included in this study had у1 of these predictors and were considered to possibly have non-catheter related infection. As expected, catheter removal at 72 h did not improve outcome (response of 56% associated with CVC removal and 53% with retention; ) in this subpopulation but was P p .78 associated with improved outcome of 90% (compared with 75% if the CVC was retained) in the small subpopulation of primary candidemia cases not associated with any of the predictors listed above. Therefore, these predictors could be useful in determining whether the primary candidemia in a patient with cancer who has a CVC is catheter related and, accordingly, whether the catheter needs to be removed (figure 2).
There are several limitations to this current study. First, its retrospective design makes it difficult to evaluate the microbiologic response (persistence of candidemia), given the fact that blood samples were not obtained for culture every day for all patients. Second is the fact that only 27% of all patients had documented catheter-related candidemia, and only 13% of the cases of primary candidemia were possibly catheter related. Third, molecular typing methods were not used to determine the relatedness of Candida species cultured from blood and catheter tips.
In conclusion, the clinician should seriously consider early removal of the CVC (р72 h after the first blood culture positive for Candida species) in a patient with no apparent source of the candidemia (except the catheter) and no previous corticosteroid or chemotherapy within 30 days of the onset of candidemia, as well as no clinical evidence of dissemination. In addition, the CVC should be removed from patients with differential quantitative blood cultures or time to positivity suggestive of catheter-related candidemia (figure 2).
